With that, Theravance expects its lifetime value from the inhaler to come out to $1.52 billion. The drug stems from a 2002 ...

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

Following Merus’ splash last month with a “best-in-disease profile” for its head and neck cancer bispecific, Bicara touted ...

Drinking coffee in the evening may keep your brain too active during sleep, affecting its ability to rest and recover.

In a new study published in the journal Nature Communications Biology, a team of researchers explored how caffeine affects ...

Radionuclide therapy with the radioactive element terbium could effectively combat lymphoma. This is demonstrated by ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response ...

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that it has entered into a definitive agreement to sell its remaining royalty interest in net sales ...

Bristol Myers Squibb partners with BioNTech in a $11.1B deal to develop BNT327, a promising cancer immunotherapy. Read more ...

AACE released clinical guidelines on the diagnosis, management, and surveillance of tumors related to multiple endocrine ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...